RecruitingNot Applicable

PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma

China150 participantsStarted 2024-07-23

Plain-language summary

This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Pathologic diagnosis of DLBCL
✓. Patient's general condition is good and survival is expected to be greater than six months
✓. Signed and dated informed consent form

Exclusion criteria

✕. Combined with other malignant tumors
✕. Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study
✕. Pregnant women and women at risk of pregnancy, breastfeeding women
✕. poor compliant

What they're measuring

The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma

Timeframe: Baseline and 2 weeks after treatment

Standardized uptake value (SUV)

Timeframe: Baseline and 2 weeks after treatment

Trial details

NCT IDNCT06755775

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-07-23

Contact for this trial

Xinyi Zhu

19121913585 zxy16zz@163.com

View on ClinicalTrials.gov More Diffuse Large B-Cell Lymphoma trials